GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases
Status:
Terminated
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study it to determine whether the use of a gonadotropin releasing hormone
(GnRH)-agonist (depot-leuprolide acetate) during cyclophosphamide (CYC) therapy in women with
rheumatic diseases will provide greater ovarian protection than placebo.
Phase:
Phase 3
Details
Lead Sponsor:
Joseph Mccune
Collaborators:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) National Institutes of Health (NIH)